INDIAN PHARMA UNDER USFDA LENS
Bio Spectrum|February 2020
India holds a major stake in the US market. Hence US Food Drug Administration (FDA) has imposed stringent regulations to meet the international regulatory requirement which further boosts number of inspections carried out at various facilities on Indian pharmaceutical companies. With the booming generics business, USFDA is keeping a sternwatch over the Indian pharma companies to safeguard the health interest of its population. The government of India has been adopting to stringent mechanisms to ensure the quality of drugs into the market. The Ministry of Health has been imposing a mandatory BA/BE studies for all the pharmaceutical manufacturing permissions. Government’s “Make in India” initiative is expected to deliver more safe, efficient and quality drugs into the market. With these and many more initiatives India will continue to be the powerhouse of pharmaceutical industry in coming years.
Jyoti Pandey
INDIAN PHARMA UNDER USFDA LENS

In 2019, the US Food Drug Administration (FDA) issued warning letters to 19 Indian pharma giants. The number has drastically increased from 10 companies in 2018. The USFDA issues warning letters to pharma companies if the products do not meet specific regulatory requirements. The warning letter makes clear that the company must correct the problem and plan in a timeframe to inform FDA for its correction, according to USFDA.

Some of the key reasons for receiving warning letters include data integrity, insufficient documentation, misleading claims about the efficacy and risks associated with the use of a drug product, significant violations of current good manufacturing practice (CGMP) regulations for finished pharmaceuticals and Active Pharmaceutical Ingredient (APIs), commercialization of unapproved or misbranded drugs.

Indian companies are at paramount of receiving warning letters owing to the rise in an inspection by the USFDA. Sharing his views on this Sudarshan Jain, Secretary-General, Indian Pharmaceutical Alliance (IPA), Mumbai says “There is an increase in FDA inspections in India from earlier 13 percent in 2018 to 17 percent YTD 2019 of global inspections this year. This is obvious given India’s contribution to the US healthcare system as every third tablet sold in the US is from India.” The USFDA which has established its office in India in 2008 has increased its inspections. In 2017, USFDA has 147 inspections which have gone up to 192 in 2018. In 2016 the number inspections done by USFDA were 176.

“India is crucial for the US market as India has got the highest number of FDA approved manufacturing facilities. Hence, vigilance on India would always be high and any issues related to quality in the US due to Indian players will bring FDA vigilance under criticism as well”, says Prashant Khadayate – Practice Head, Healthcare, GlobalData.

This story is from the February 2020 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

This story is from the February 2020 edition of Bio Spectrum.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.

MORE STORIES FROM BIO SPECTRUMView All
Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities
Bio Spectrum

Agilent releases nextgen HPLC systems with enhanced automation and sustainability capabilities

Agilent Technologies Inc. has announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions.

time-read
1 min  |
BioSpectrum India Dec 2024
Univercells Technologies launches miniaturised scale-X Nexo Bioreactor
Bio Spectrum

Univercells Technologies launches miniaturised scale-X Nexo Bioreactor

Univercells Technologies has announced the launch of its latest innovation, the scale-X nexo bioreactor.

time-read
1 min  |
BioSpectrum India Dec 2024
Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics
Bio Spectrum

Thermo Fisher and Telangana to establish Bioprocess Design Centre for novel biotherapeutics

Thermo Fisher Scientific has announced the signing of a Memorandum of Understanding (MoU) with the Government of Telangana to establish a Bioprocess Design Centre (BDC) in Genome Valley, Hyderabad.

time-read
1 min  |
BioSpectrum India Dec 2024
VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors
Bio Spectrum

VFL Sciences announces launch of GreatFlo Parallel Bioreactors and Fermentors

Chennai-based VFL Sciences has announced the launch of GreatFlo Parallel, a range of seamlessly parallel Bioreactors and Fermentors at the IKMC 2024 event organised by IKP Knowledge Park at Hyderabad recently, by Dr Jitendra Kumar, Managing Director, BIRAC.

time-read
1 min  |
BioSpectrum India Dec 2024
Avantor opens new innovation centre for solving life science's biggest challenges
Bio Spectrum

Avantor opens new innovation centre for solving life science's biggest challenges

Avantor, Inc., a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, has announced the opening of its new flagship Bridgewater Innovation Centre.

time-read
1 min  |
BioSpectrum India Dec 2024
Waters unveils new software to deliver lab-centric business intelligence
Bio Spectrum

Waters unveils new software to deliver lab-centric business intelligence

Waters Corporation has announced the launch of waters connect Data Intelligence software, a new cloud-based application that helps customers in regulated industries improve how they access, organise, analyse, and drive productivity from laboratory information.

time-read
1 min  |
BioSpectrum India Dec 2024
INST develops unique drug delivery method to improve treatment of brain TB
Bio Spectrum

INST develops unique drug delivery method to improve treatment of brain TB

Researchers at the Institute of Nano Science and Technology (INST), Mohali, have created a unique way to deliver Tuberculosis (TB) medicines directly to the brain bypassing the challenging blood-brain barrier (BBB) that limits the effectiveness of many brain TB medicines.

time-read
1 min  |
BioSpectrum India Dec 2024
New way to create hydrogels from viral protein fragments for improving drug delivery
Bio Spectrum

New way to create hydrogels from viral protein fragments for improving drug delivery

Researchers from Bose Institute, an autonomous institute of the Department of Science and Technology (DST), in Kolkata, have discovered a new way to create hydrogels using tiny protein fragments of just five amino acids from the SARS-CoV-1 virus, that could help improve targeted drug delivery & reduce side effects.

time-read
1 min  |
BioSpectrum India Dec 2024
Lupin appoints Claus Jepsen as President, Global Specialty
Bio Spectrum

Lupin appoints Claus Jepsen as President, Global Specialty

Global pharma major Lupin has announced the appointment of Claus Jepsen as President, Global Specialty.

time-read
1 min  |
BioSpectrum India Dec 2024
Shyamakant Giri to join as CEO of Gland Pharma
Bio Spectrum

Shyamakant Giri to join as CEO of Gland Pharma

Gland Pharma’s Board has approved the appointment of Shyamakant Giri, as the new Chief Executive Officer (CEO) of the company.

time-read
1 min  |
BioSpectrum India Dec 2024